Sign in Subscribe
United States. Securities and Exchange Commission

Amgen Inc. Files SEC Form 4 Notification

Strategic Insights

— 1 min read

According to a U.S. Securities and Exchange Commission (SEC) filing, Amgen Inc. submitted a Form 4 notification on November 9, 2021, disclosing changes in ownership of the company's equity securities. The Form 4 filing is a required statement for directors, officers, or owners with more than 10% ownership in a class of equity securities registered under Section 12 of the Securities Exchange Act of 1934. The filing provides detailed information on the reporting person's relationship to the company and their purchases and sales of equity securities.

Key Takeaways:

  • Amgen Inc. filed a Form 4 notification with the SEC on November 9, 2021, reporting changes in ownership of the company's equity securities.
  • The filing is required for directors, officers, or owners with more than 10% ownership in a class of equity securities registered under Section 12 of the Securities Exchange Act of 1934.
  • The Form 4 filing provides detailed information on the reporting person's relationship to the company, including their purchases and sales of equity securities.
  • The SIC code for Amgen Inc. is 2836, Biological Products, (No Diagnostic Substances), and the contact information for the company is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320, (805)447-1000.
  • The SEC filing is a formal document submitted by publicly-traded companies to disclose changes in ownership or other financial information.

Statistics:

  • The Form 4 filing was submitted on November 9, 2021.
  • The SIC code for Amgen Inc. is 2836.
  • The company's contact information is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320, (805)447-1000.

Sources:

  • NewsRx
  • *U.S. Securities and Exchange Commission (SEC): Form 4*/
  • *Amgen Inc.: SEC Filing*/

Read more